Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women

被引:2
|
作者
Upson, Kristen [1 ]
Harmon, Quaker E. [2 ]
Heffron, Renee [3 ,4 ]
Hall, Janet E. [5 ]
Wise, Lauren A. [6 ]
Wegienka, Ganesa [7 ]
Tokar, Erik J. [8 ]
Baird, Donna D. [2 ]
机构
[1] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, 909 Wilson Rd,Room 601, E Lansing, MI 48824 USA
[2] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA
[3] Univ Washington, Dept Global Hlth, Seattle, WA USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[5] NIEHS, Clin Res Branch, Res Triangle Pk, NC USA
[6] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA USA
[7] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA
[8] NIEHS, Stem Cells Toxicol Grp, Natl Toxicol Program Lab, Div Natl Toxicol Program, Res Triangle Pk, NC USA
基金
美国国家卫生研究院;
关键词
HUMAN VAGINAL HISTOLOGY; BONE-MINERAL DENSITY; HORMONAL CONTRACEPTION; MOBILIZATION; PERIMENOPAUSAL; PREMENOPAUSAL; OSTEOPOROSIS; PREGNANCY; EFFICACY; THERAPY;
D O I
10.1289/EHP7017
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the toxic metal lead stored in bone to blood, presenting users with increased systemic exposure to lead. OBJECTIVE: The objective of our study was to investigate the association between current DMPA use and blood lead concentrations. METHODS: We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1,693 African-American women who were 23-35 years of age. Data on DMPA use were collected by computer-assisted telephone interview. Blood lead concentrations were measured in whole blood samples among 1,548 participants (91% of cohort). We estimated the adjusted percent difference in blood lead concentrations and 95% confidence intervals (CI) between current DMPA users and nonusers using multivariable linear regression. RESULTS: Geometric mean blood lead concentration was 0:69 lg=dL (95% CI: 0.67, 0.71). After adjustment, current DMPA users (7% of cohort) had blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%, 29%). Similar associations were observed with additional analyses to assess for potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior year, and history of medical conditions or current medication use associated with bone loss. DISCUSSION: Our results indicate that current DMPA use is associated with increased blood lead concentrations. Further research, particularly in populations highly exposed to lead, is warranted to consider tradeoffs between the adverse effects of lead on human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy.
引用
收藏
页码:117004 / 1
页数:7
相关论文
共 50 条
  • [41] Accounting for Anovulation and Vaginal Thinning During Depot Medroxyprogesterone Acetate Use
    Atrio, Jessica
    JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (05): : 850 - 850
  • [42] Depot Medroxyprogesterone Acetate Use Is Not Associated With Risk of Incident Sexually Transmitted Infections Among Adolescent Women
    Romer, Amy
    Shew, Marcia L.
    Ofner, Susan
    Gilliam, Melissa L.
    Martins, Summer L.
    Fortenberry, J. Dennis
    JOURNAL OF ADOLESCENT HEALTH, 2013, 52 (01) : 83 - 88
  • [43] A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate
    Wernick, Hunter J.
    Wentzel, Evelyn
    Jackson, Kenneth
    Schmuhl, Kelsey
    Valenti, Olivia
    Bonny, Andrea E.
    Berlan, Elise D.
    JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2023, 36 (06) : 549 - 552
  • [44] Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance
    Sorensen, MB
    Collins, P
    Ong, PJL
    Webb, CM
    Hayward, CS
    Asbury, EA
    Gatehouse, PD
    Elkington, AG
    Yang, GZ
    Kubba, A
    Pennell, DJ
    CIRCULATION, 2002, 106 (13) : 1646 - 1651
  • [45] Activity of CYP3A4 and CYP2C19 in Young Women Who Use Depot Medroxyprogesterone Acetate (DMPA)
    Kimble, Thomas
    Sager, Jennifer
    Isoherranen, Nina
    Nnadi, Laura
    Archer, Davi
    Ballagh, Susan
    OBSTETRICS AND GYNECOLOGY, 2016, 127 : 120S - 121S
  • [46] Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum
    Tepper, Naomi K.
    Jeng, Gary
    Curtis, Kathryn M.
    Boutot, Maegan E.
    Boulet, Sheree L.
    Whiteman, Maura K.
    OBSTETRICS AND GYNECOLOGY, 2019, 133 (03): : 533 - 540
  • [47] Vaginal atrophy and genital pain in women on depot medroxyprogesterone acetate contraceptive injection
    Perkins, Nicky
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2024, 64 (02): : 160 - 164
  • [48] Depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
    Scholes, D
    LaCroix, A
    Ichikawa, L
    Barlow, W
    Ott, S
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S235 - S235
  • [49] THE EFFECT OF DEPOT-MEDROXYPROGESTERONE ACETATE ON RESTING METABOLIC RATE IN PREMENOPAUSAL WOMEN
    Steward, R. G.
    Stanczyk, F. Z.
    Price, T. M.
    FERTILITY AND STERILITY, 2014, 102 (03) : E254 - E254
  • [50] Estrogen-Containing Contraceptive Use and Blood Lead Concentrations in a Cohort of Young Women
    Chapman, Lauren E.
    Upson, Kristen
    Hall, Mandy S.
    Harmon, Quaker E.
    Wise, Lauren A.
    Wegienka, Ganesa
    OBSTETRICS AND GYNECOLOGY, 2024, 143 (5S): : 9S - 9S